¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15
±³À°ÀÏÀÚ : 2023-04-15
±³À°Àå¼Ò : ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦

±³À°ÁÖÁ¦ : Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ

´ã´çÀÚ : ´ëÇѳú¿°³ú¿°ÁõÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-2072-0629

À̸ÞÀÏ : encephalitis.office@kens.or.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:00~09:30 ÇöÀåµî·Ï ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:30~09:45 A 31-year-old female with Refractory Primary CNS Vasculitis: What is the next possible alternative therapy? ÀåÀ±Çõ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 09:45~10:00 Neuronal Intranuclear Inclusion Disease in an Adult Patient: A Diagnostic Challenge ½Å¿ë¿ì(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:00~10:15 A 46-year old man with new-onset seizures È«»óºó(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:15~10:30 25-year-old woman with drug resistant epilepsy : A case of autoimmune epilepsy ÀÌÀ±°æ(µ¿¾Æ´ëº´¿ø)

ÈÞ½Ä 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:30~10:50 COFFEE BREAK ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 10:50~11:05 A case of LGI-1 antibody encephalitis with schizophrenia like symptom as an initial clinical manifestation ¼Û¿øºó(°¡Å縯°üµ¿´ë ±¹Á¦¼º¸ðº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:05~11:20 Scrub typhus ±è±ÙÅÂ(°è¸í´ëµ¿»êº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:20~11:35 A case of multiple cranial neuropathy after zoster ophthalmicus Ȳ¼ºÀº()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:35~11:50 An 18-year-old male with seizure and anti-N-methyl-D-aspartate receptor antibody ±èÅÂÁØ(¾ÆÁִ뺴¿ø)

½Ä»ç 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 11:50~13:00 LUNCH ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:00~13:25 VTE treatment and Prophylaxis for Neurologic patient ³ª»óÈÆ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:25~13:50 Immunotherapy and infection risk ÀÌÇÑ»ó(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 13:50~14:15 Psychiatric symptom care in neurologic ward ±è¹Î¾Æ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 14:15~14:40 Breaking bad news and ethical decision À̼øÅÂ(¼­¿ï´ëº´¿ø)

ÈÞ½Ä 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 14:40~15:00 COFFEE BREAK ()

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:00~15:25 Glymphatic evaluation using MRI ÃÖ½ÂÈ«(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:25~15:50 Macrophage activation syndrome ¹ÚÁø±Õ(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 15:50~16:15 Seizure management in encephalitis patients ÁÖ°Ç(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 04-15 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼­¼ºÈ¯¿¬±¸È¦ 16:15~16:40 Recent Advances in Gene Therapy for Rare Diseases ¹®Àå¼·(¼­¿ï´ëº´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦ 19 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2023-04-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦43ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2023-04-15
´ÙÀ½±Û ±¹¸³Áß¾ÓÀÇ·á¿ø Àü¹® ±âµµ°ü¸® ½Ã¹Ä·¹ÀÌ¼Ç : 2023-04-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
17 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ôÃߺ´¿ø 8¿ù ¿ù·ÊÁý´ãȸ : 2018-08-02 0 376 2018-07-28
16 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-01 0 390 2018-07-28
15 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ Á¦3Â÷ CADAVER WORKSHOP : 2018-07-29 0 754 2018-07-28
14 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø ¿µ»óȹµæÀÇ ±â¼úÀû Ãø¸é°ú Æó¾Ï °ËÁø : 2018-07-29 0 744 2018-07-28
13 ¼­¿ï ´ëÇѺÎÀÎÁ¾¾çÇÐȸ KGOG 2018 Summer Workshop Uterine Cancer : 2018-07-29 0 924 2018-07-28
12 ¼­¿ï ´ëÇÑ¿µ»óÀÇÇÐȸ »ó±ÙÀÇ»ç À¯¹æÃÔ¿µ¿ëÀåÄ¡ Ç°Áú°ü¸® ±³À° 3ÀÏÂ÷(7¿ù29ÀÏ) : 2018-07-29 0 856 2018-07-28
11 ¼­¿ï ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2018³âµµ ¡ººÐ¼®½É¸®ÇÐ ±âÃÊ°­Á¡»: 2018-07-29 0 879 2018-07-28
10 ¼­¿ï °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 18 ȸ ü°èÀû ¹®Çå °íÂû[¸ÞŸºÐ¼®]À» ÅëÇÑ ³í¹®Ãâ°£ ¿öÅ©¼¥ : 2018-07-28 0 1,209 2018-07-28
9 °æ±â ¸íÁöº´¿ø ¿äÃò ¹× ½½°üÀý ÅëÁõ Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2018-07-28 0 1,173 2018-07-28
8 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ Á¦3Â÷ CADAVER WORKSHOP : 2018-07-28 0 1,133 2018-07-28
7 ¼­¿ï ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ 2018³â ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ ¿¬¼ö°­Á : 2018-07-28 0 1,051 2018-07-28
6 °æ±â ´ëÇѳ»½Ã°æº¹°­°æ¿Ü°úÇÐȸ 2018 Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC) Symposium : 2018-07-28 0 1,296 2018-07-28
5 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø Hyperhidrosis Symposium : 2018-07-28 0 1,578 2018-07-28
4 ¼­¿ï °¡Å縯´ëÇб³¿©Àǵµ¼º¸ðº´¿ø 2018 The 11th Catholic Neurosurgery Update Symposium : 2018-07-28 0 1,458 2018-07-28
3 °æ±â ´ëÇÑ´ç´¢º´ÇÐȸ °æÀÎÁöȸEGDM (Essential Guideline to Diabetes Management) : 2018-07-28 0 2,263 2018-07-28
1411 | 1412 | 1413 | 1414 | 1415
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷